Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Assessment of the efficacy and safety of dupilumab combined with cyclosporine A in patients with atopic dermatitis

Xiaotao Liu, Lifeng Wang, Lingling Zheng

Department of Dermatology, Beijing Luhe Hospital, Capital Medical University, Beijing, China;

For correspondence:- Lingling Zheng Email: lxt19761010@163.com

Accepted: 28 June 2023 Published: 31 July 2023

Citation: Liu X, Wang L, Zheng L. Assessment of the efficacy and safety of dupilumab combined with cyclosporine A in patients with atopic dermatitis. Trop J Pharm Res 2023; 22(7):1463-1468 doi: 10.4314/tjpr.v22i7.15

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To assess the efficacy and safety of dupilumab combined with cyclosporine A in patients with atopic dermatitis.

Methods: This retrospective study enrolled 100 patients with atopic dermatitis who received treatment at Beijing Luhe Hospital between November 2020 and November 2022. The patients were randomly divided into two groups, namely, treatment group and comparison group, with 50 cases in each group. Comparison group received cyclosporine A, while the treatment group received dupilumab in addition to cyclosporine A. The various fficacy scores and adverse reactions between the two groups were recorded and compared.

Results: After treatment, skin lesion area and severity, EASI score, NRS score, SCORAD score, POEM score and DLQI score in the treatment group were significantly lower than those in the comparison group (p < 0.05).

Conclusion: The combination of dupilumab and cyclosporine A significantly alleviates the symptoms of acne and pruritis, as well as reduce the area of skin lesions in patients with atopic dermatitis. This treatment also enhances the quality of life of the patients. However, further but larger clinical trials are required prior to adoption of this combination treatment in clinical practice.

Keywords: Dupilumab, Cyclosporine A, Atopic dermatitis, Quality of life, Drug allergy